SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
SEC Accession No. 0001193125-19-194012
Filing Date
2019-07-15
Accepted
2019-07-15 16:15:56
Documents
1
Group Members
AISLING CAPITAL PARTNERS IV LLCAISLING CAPITAL PARTNERS IV, LPANDREW SCHIFFSTEVE ELMS

Document Format Files

Seq Description Document Type Size
1 SC 13G/A d761474dsc13ga.htm SC 13G/A 109096
  Complete submission text file 0001193125-19-194012.txt   110885
Mailing Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080 650-266-3500
SUNESIS PHARMACEUTICALS INC (Subject) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-81034 | Film No.: 19955352
SIC: 2834 Pharmaceutical Preparations

Mailing Address 888 SEVENTH AVENUE, 12TH FLOOR NEW YORK NY 10106
Business Address 888 SEVENTH AVENUE, 12TH FLOOR NEW YORK NY 10106 212-651-6380
Aisling Capital IV, LP (Filed by) CIK: 0001652910 (see all company filings)

IRS No.: 474953768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A